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Aim: To investigate seven CA125 criteria to monitor progressive ovarian cancer among 
patients with stage IC–IV disease. Materials & methods: Four criteria were used to asses 
CA125 increments starting from concentrations ≥35 U/ml and three criteria to asses 
increments starting from concentrations <35 U/ml. Results: A total of 231 patients 
were allocated to CA125 monitoring. The performances of the CA125 criteria were 
similar with sensitivities of 30–55%, negative predictive values of 28–46%, positive 
predictive values of 90–100% and median lead times of 26–87 days. Conclusion: The 
criteria showed low sensitivity and inability to exclude progressive ovarian cancer. The 
study suggests that CA125 information cannot stand alone but should be considered 
used in conjunction with other investigative procedures.
Lay Abstract: Few have validated the CA125 progression criteria proposed by Rustin 
et al. in 1996 and in 2001. These two criteria were officially recommended by the 
Gynecological Cancer Intergroup to be incorporated into clinical trials in 2010. Among 
other criteria, we validated the Gynecological Cancer Intergroup CA125 progression 
criteria in an ovarian cancer population regarding sensitivity, specificity, positive 
predictive value and negative predictive value. We found that the criteria had low 
sensitivity and ability to exclude tumor growth. We believe that the clinical utility 
of CA125 may be questioned, and there is a need for supplementary markers and 
alternative assessment criteria.
First draft submitted: 8 February 2017; Accepted for publication: 24 April; Published 
online: 18 July 2017
Keywords:  assessment CA125 criteria • CA125 • CA125 increments • clinical progression  
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A change of tumor size is routinely measured 
by radiological imaging according to the 
Response Evaluation Criteria in Solid Tumors 
(RECIST 1.1) [1]. However, this may be dif­
ficult among patients with ovarian cancer as 
they often have no macroscopic detectable 
disease after initial surgery or they present 
with widespread diffuse peritoneal meta­
stases [2–4]. The serological tumor marker, 
cancer antigen (CA125), is frequently added 
as a biochemical monitor of patients with 
epithelial ovarian/fallopian tube or primary 
serous peritoneal cancer [5]. However, it is 
a challenge to define increments of CA125 
concentrations that reliably correlate with 
increasing tumor burden, in other words, 
recurrence and progressive disease. In the last 
three decades, a number of evaluation crite­
ria have been proposed to interpret serially 
increasing CA125 concentrations [5–20].
Recently, a systematic review [21] identified 
seven criteria to assess CA125 increments 
from below to above the applied cut­off con­
centration and from above the applied cut­
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off to higher levels as proposed by Rustin et al. [6,8] 
and by Tuxen et al. [7,20]. The criteria by Rustin et al. 
were generated from epithelial ovarian cancer (EOC) 
patients during follow­up after first­line chemotherapy 
and incorporated into the RECIST 1.1 by the Gyne­
cological Cancer Intergroup [1]. The criteria suggested 
by Tuxen et al. were generated from ovarian cancer 
patients monitored during first­line chemotherapy as 
well as the subsequent control period [7,20]. The seven 
criteria identified in the review were further com­
pared in a Phase I monitoring trial according to the 
design recommendations from the European Group 
on Tumor Markers (EGTM) [22]. They were compared 
under standardized conditions, and their individual 
ability to detect early tumor growth was evaluated in a 
preclinical model system based on computer simulated 
CA125 concentrations [23].
The current Phase II monitoring study estimated 
whether the criteria that performed the best [24] in 
the simulation model also performed the best when 
applied to serial CA125 concentrations obtained from 
ovarian cancer patients monitored during first­line 
chemotherapy and the postchemotherapy follow­up 
period [23]. The study also estimated whether the cri­
teria introduced by Rustin et al. were useful during 
first­line chemotherapy even though their criteria were 
generated from patients during follow­up after first­
line chemotherapy. Overall, the current study was per­
formed to challenge a previous report by Rustin et al. 
which suggested that CA125 should not be used as 
a standard test for monitoring patients with ovarian 
cancer.
Materials & methods 
Design
The study complied with the general recommenda­
tions for study design as specified by the Standards for 
Reporting Diagnostic Accuracy Studies (STARD) [25]. 
However, it was not a cross­sectional diagnostic study 
but a longitudinal monitoring trial based on serial 
measurements of CA125 among individual patients. 
Additionally, the study followed a phased approach as 
proposed by the EGTM and was designed as a prospec­
tive Phase II biomarker monitoring trial embedded 
Figure 1. Assessment criteria for serial CA125 concentrations during patient monitoring. (A) CA125 increments 
starting above the cut-off. (B) CA125 increments starting below the cutoff. CD denotes the required critical 
difference. RCV denotes the reference change value. 
†Criterion 1B showed the best monitoring performance for increments starting above the applied cut-off in the 
simulation models [23].
‡Criterion 2A showed the best monitoring performance for increments starting below the applied cut-off in the 
simulation models [23].
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Table 1. Characteristics of ovarian cancer patients eligible for CA125 monitoring.
Patients characteristics 189 patients eligible for first-line chemotherapy
Age (years)
– Median 59
– Range 33–78
FIGO stage of disease no.
– IC 14
– IIA 2
– IIB 11
– IIC 13
– IIIA 12
– IIIB 18
– IIIC 89
– IV 29
– Not reported 1
WHO performance no. [30]
– 0 118
– 1 54
– 2 11
– 3 3
– 4 0
– Not reported 3
Histological type no.
– Serosa 112
– Mucinous 5
– Clear cell 9
– Endometrioid 13
– Undifferentiated 27
– Mixed 10
– Borderlines, mixed mullerian tumor, mixed mesodermal tumor, Brenner 
tumor, and peritoneal serous adenocarcinoma
12
– Not reported 1
Histological grade
– Poorly differentiated, no. 86
– Moderately differentiated 34
– Well differentiated 19
– Not reported 50
Residual tumor size after surgery before chemotherapy no.
0 cm 16
<1 cm 50
1–10 cm 65
>10 cm 55
– Not reported 3
FIGO: International Federation of Gynecology and Obstetrics.
10.4155/fsoa-2017-0023 Future Sci. OA (2017) 3(3), FSO216 future science group
Research Article    Abu Hassan, Nielsen, Tuxen, Petersen & Sölétormos
into clinical drug trials where the tumor marker inves­
tigation was secondary to the clinical drug trial [22,26]. 
Accordingly, the clinical information and the results 
of the imaging analysis were available to the staff at 
the ward, and so were the CA125 concentrations. 
Phase II monitoring trials validate the performance of 
the investigated biomarker in patient cohorts by apply­
ing assessment criteria for marker progression that were 
identified as promising by previous preclinical Phase I 
trials. Phase II monitoring trials estimate the ability of 
the biomarker to identify, exclude and predict a change 
in disease status.
Patients
Patients with newly diagnosed, histologically verified 
EOC with International Federation of Gynecology 
and Obstetrics (FIGO) stages IC–IV were included. 
The study was conducted at the Departments of 
Oncology, Herlev and Gentofte Hospital as well as 
Nordsjællands Hospital during 1995–2001. Date of 
primary surgery, the beginning and the end of first­
line chemotherapy as well as follow­up were registered 
for all patients. Evaluation of the disease by gyneco­
logical examination, ultrasound and/or computer 
tomography was repeated at every third treatment 
cycle, and every 3 months during the first 3 years of 
follow­up and every 6 months thereafter until a total 
surveillance period of 5 years. Additional evaluations 
were performed when clinically indicated. The clini­
cal status in terms of progressive disease was recorded 
according to the WHO criteria because these were in 
use at the time of the clinical evaluations [27]. The clin­
ical evaluations according to the WHO criteria were 
the reference against which the results of the CA125 
evaluations were compared. The study was approved 
by the Regional Ethical Committees (KA 94162m) 
(H–3–2013–FSP43) and The Danish Data Protection 
Agency (1995–1200–655), (2013–41–2366). The 
databank with the cumulated clinical and CA125 data 
was assessed in 2015.
Collection of blood samples
Samples were collected on the days of treatment and 
the days of clinical evaluation. Additionally, if possi­
ble, samples were collected when routine analytes were 
requested outside the scheduled time points.
CA125 measurements
Concentrations in serum were measured prospectively 
a few days after sample collection with the ELISA–
CA125 II assay, a solid­phase two­site immune radio­
metric assay, from CIS Bio International. Following 
August 1996, the CA125 concentrations were mea­
sured with the Immuno 1 CA125 II assay, a one­step 
solid phase enzyme immunoassay, from Bayer. The ref­
erence interval (the 95 percentile value) used for both 
assays was <35 U/ml as recommended by Bast et al. [5].
Quality assurance
To ensure a stable analytical quality throughout the 
study, three control samples were included in each 
assay run having different concentrations of the ana­
lytes. A Westgard multirule combination was used to 
accept or reject runs [28]. The analytical imprecision 
comprised both the intra­ and the interassay variation 
because each sample from an individual subject was 
analyzed consecutively in different assay runs.
Criteria to interpret CA125 increments
Seven criteria were tested during first­line chemother­
apy and the subsequent follow­up period (Figure 1). 
Four criteria were tested for increments starting from 
baseline concentrations above cut­off to higher levels 
(Figure 1A), and three criteria were tested for incre­
ments from below to above cut­off (Figure 1B). In both 
situations, Rustin et al. used an approach by which the 
increment between two concentrations had to exceed 
a defined arbitrary percentage of change before con­
sidered indicative of progression [6,8]. Tuxen et al. [20] 
used two approaches to generate their CA125 assess­
ment criteria. Their first approach involved a statistical 
Table 2. First-line chemotherapy among 189 patients eligible for CA125 monitoring.
Treatment modalities No. of patients
Paclitaxel and carboplatin 89
Paclitaxel, carboplatin and gemcitabine 42
Paclitaxel and cisplatin 39
Cyclophosphamide and carboplatin 9
Treosulfan 7
Paclitaxel 1
Cyclophosphamide, doxorubicin and cisplatin 1
Carboplatin 1
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Table 3. Ability of the applied CA125 assessment criteria to identify and exclude progressive ovarian cancer 
cumulated from first-line chemotherapy and follow-up.
Criteria as 
provided in 
Figure 1 
Number of TP, 
FP, FN and TN 
events
Sensitivity,% 
(95% CI)
Specificity,% 
(95% CI)
Positive 
predictive 
value, % 
(95% CI)
Negative 
predictive 
value, % 
(95% CI)
FP rate, % 
(95% CI)
FN rate, % 
(95% CI)
Ref.
3A All histological tumor types 
Criterion 1A, 
Rustin et al.†
14 TP, 0 FP 
Z16 FN, 8 TN
47 (31–63) 100 (67–100) 100 (79–100) 33 (18–52) 0 (0–33) 53 (37–6) [8]
Criterion 1B, 
Tuxen et al.†
9 TP, 0 FP 
21 FN, 8 TN
30 (17–47) 100 (67–100) 100 (70–100) 28 (15–45) 0 (0–33) 70 (53–83) [7,20]
Criterion 1C, 
Tuxen et al.†
14 TP, 0 FP 
16 FN, 8 TN
47 (31–63) 100 (67–100) 100 (79–100) 33 (18–52) 0 (0–33) 53 (37–69) [7,20]
Criterion 1D, 
Tuxen et al.†
13 TP, 0 FP 
17 FN, 8 TN
43 (28–60) 100 (67–100) 100 (78–100) 32 (17–51) 0 (0–33) 57 (40–72) [7,20]
Criterion 2A, 
Rustin et al.‡
43 TP, 3 FP 
61 FN, 44 TN
41 (33–50) 94 (84–98) 94 (84–98) 42 (39–51) 6 (2–16) 59 (50–67) [6]
Criterion 2B, 
Tuxen et al.‡
50 TP, 3 FP 
54 FN, 44 TN
48 (40–57) 94 (84–98) 94 (86–98) 45 (36–54) 6 (2–16) 52 (43–60) [7,20]
Criterion 2C, 
Tuxen et al.‡
53 TP, 4 FP 
51 FN, 43 TN
51 (43–59) 92 (81–97) 93 (84–98) 46 (37–55) 8 (3–19) 49 (41–57) [7,20]
3B Serous epithelial tumors
Criterion 1A, 
Rustin et al.§
9 TP, 0 FP 
11 FN, 5 TN
45 (26–65) 100 (52–100) 100 (70–100) 31 (13–55) 0 (0–48) 55 (35–74) [8]
Criterion 1B, 
Tuxen et al.§
8 TP, 0 FP 
12 FN, 5 TN
40 (22–61) 100 (52–100) 100 (66–100) 29 (12–53) 0 (0–48) 60 (39–78) [7,20]
Criterion 1C, 
Tuxen et al.§
11 TP, 0 FP 
9 FN, 5 TN
55 (35–74) 100 (52–100) 100 (74–100) 36 (15–61) 0 (0–48) 45 (26–65) [7,20]
Criterion 1D, 
Tuxen et al.§
10 TP, 0 FP 
10 FN, 5 TN
50 (30–70) 100 (52–100) 100 (72–100) 33 (14–58) 0 (0–48) 50 (30–70) [7,20]
Criterion 2A, 
Rustin et al.¶
29 TP, 3 FP 
35 FN, 20 TN
45 (35–56) 87 (69–96) 91 (77–97) 36 (26–84) 13 (4–31) 55 (44–65) [6]
Criterion 2B, 
Tuxen et al.¶
32 TP, 3 FP 
32 FN, 20 TN
50 (39–61) 87 (69–96) 91 (79–98) 39 (27–51) 13 (4–31) 50 (39–61) [7,20]
Criterion 2C, 
Tuxen et al.¶
34 TP, 4 FP 
30 FN, 19 TN
53 (42–64) 83 (64–94) 90 (77–96) 39 (27–52) 17 (6–36) 47 (36–58) [7,20]
TP denotes true-positive results: concordant clinical and CA125 progression with a lead time of ≥0 days.
FP denotes false-positive results: discordant clinical and CA125 information with CA125 progression without clinical progression.
TN denotes true-negative results: concordant clinical and CA125 information in terms of nonprogression.
FN denotes false-negative results: discordant clinical and CA125 information with clinical progression without CA125 progression or negative CA125 lead time.
( ): Two-sided 95% CI (%).
†CA125 baseline concentration above the applied cut-off among 38/189 eligible patients; 30/38 patients developed clinical progression.
‡CA125 baseline concentration below the applied cut-off among 151/189 eligible patients; 104/151 patients developed clinical progression.
§CA125 baseline concentration above the applied cut-off among 25/112 eligible patients; 20/25 patients developed clinical progression.
¶CA125 baseline concentration below the applied cut-off among 87/112 eligible patients; 64/87 patients developed clinical progression.
estimate of the significance of an increment based on 
the analytical and within­subject biological variations 
of CA125, termed the reference change value. Their 
second approach was similar to the approach used by 
Rustin et al. [6,8,22].
The assessment criteria were applied to the serial 
CA125 concentrations for each patient; the date of 
CA125 progression provided by each criterion was 
registered; and the clinical and marker evaluations in 
terms of progression were matched. The time interval 
between CA125 progression and clinical progression 
(lead time) for each criterion was calculated. The lead 
time was positive (>0 days) when marker progression 
preceded clinical progression. There was no lead time 
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(= 0 days) if the clinical progression and the marker 
progression were obtained simultaneously. The lead 
time was negative (<0 days) when the clinical pro­
gression preceded the marker progression. When a 
clinical evaluation and a marker assessment differed, 
the data were registered as discordant; identical data 
were registered as concordant. Thus, the true­positive 
(TP) results denoted concordant information in terms 
of progressive disease with lead time ≥0 days. True­
negative (TN) results denoted concordant informa­
tion in terms of nonprogression. False­negative (FN) 
results denoted discordant information when there was 
clinical progression without CA125 progression. False­
positive (FP) results denoted discordant information 
when CA125 progression was not followed by clinical 
progression.
Statistics
A power calculation of the sample size was performed 
prior to opening the Phase II trial database. For a cri­
terion to be valid for detecting CA125 increments it 
was assumed that the criterion should provide 70 TP 
signals in terms of progressive disease. By fixating the 
type 1 error on 0.05 and the type 2 error on 0.10, cal­
culation of power showed that a total of 156 patients 
should be included for each criterion in order to detect 
a difference in their performance. The number of TP, 
FN, FP and TN results was counted. The sensitivi­
ties (the percentage of patients with tumor growth 
detected by CA125 increments), the specificities (the 
percentage of patients without new tumor growth 
confirmed by unchanged CA125 concentrations), 
the positive predictive values (the probability of clini­
cal progression following CA125 progression), the 
negative predictive values (the probability of clini­
cal nonprogression, given a marker nonprogression), 
the FP rates (the percentage of CA125 increments 
among patients without new tumor growth) and the 
FN rates (the percentage without CA125 increments 
among patients with new tumor growth) were calcu­
lated. The 95% CI were estimated according to Geigy 
 formulas 771 and 772 [29].
Table 4. CA125 lead times among progressive ovarian cancer patients provided by the applied assessment criteria 
cumulated from first-line chemotherapy and follow-up.
Criteria as provided in 
Figure 1 
Median, days 
(range) No. (%) 
≥0 days No. 
(%)
>0 days No. 
(%)
≤0 days No. 
(%)
= 0 days No. 
(%)
<0 days No. 
(%)
Ref.
Lead times 
4A All histological tumor types
Criterion 1A, Rustin et al.† 60 (0–248) 14 (47) 13 (43) 1 (3) 1 (3) 0 [8]
Criterion 1B, Tuxen et al.† 27 (0–257) 9 (30) 7 (23) 3 (10) 2 (7) 1 (3) [7,20]
Criterion 1C, Tuxen et al.† 87 (0–356) 14 (47) 13 (43) 2 (7) 1 (3) 1 (3) [7,20]
Criterion 1D, Tuxen et al.† 66 (0–356) 13 (43) 12 (40) 3 (10) 1 (3) 2 (7) [7,20]
Criterion 2A, Rustin et al.‡ 41 (0–369) 43 (41) 35 (34) 30 (29) 8 (8) 22 (21) [6]
Criterion 2B, Tuxen et al.‡ 45 (0–775) 50 (48) 48 (46) 15 (14) 2 (2) 13 (13) [7,20]
Criterion 2C, Tuxen et al.‡ 46 (0–775) 53 (51) 51 (49) 16 (15) 2 (2) 14 (13) [7,20]
4B Serous epithelial tumors
Criterion 1A, Rustin et al.§ 66 (0–248) 9 (45) 8 (40) 1 (5) 1 (5) 0 [8]
Criterion 1B, Tuxen et al.§ 26 (0–75) 8 (40) 6 (30) 2 (10) 2 (10) 0 [7,20]
Criterion 1C, Tuxen et al.§ 85 (0–169) 11 (55) 10 (50) 1 (5) 1 (5) 0 [7,20]
Criterion 1D, Tuxen et al.§ 76 (0–169) 10 (50) 9 (45) 2 (10) 1 (5) 1 (5) [7,20]
Criterion 2A, Rustin et al.¶ 30 (0–269) 29 (45) 25 (39) 18 (28) 4 (6) 14 (22) [6]
Criterion 2B, Tuxen et al.¶ 47 (0–406) 32 (50) 31 (48) 7 (11) 1 (2) 6 (9) [7,20]
Criterion 2C, Tuxen et al.¶ 52 (0–406) 34 (53) 33 (52) 9 (14) 1 (2) 8 (13) [7,20]
†Criteria 1A–1D assessed CA125 increments among 20% (38/189) of the eligible patients with baseline concentrations above the applied cut-off; 79% (30/38) of the 
patients developed clinical progression.
‡Criteria 2A–2C to assess CA125 increments among 80% (151/189) of the eligible patients with baseline concentrations below the applied cut-off; 69% (104/151) of 
the patients developed clinical progression.
§Criteria 1A–1D assess CA125 increments among 22% (25/112) of the eligible patients with baseline concentrations above the applied cut-off; 80% (20/25) of the 
patients developed clinical progression.
¶Criteria 2A–2C to assess CA125 increments among 78% (87/112) of the eligible patients with baseline concentrations below the applied cut-off; 74% (64/87) of the 
patients developed clinical progression.
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Results
A total of 231 patients were allocated to first­line 
chemo therapy. Forty­two patients were excluded: 16 
due to insufficient sampling, 15 for other primary 
malignancy, 6 for death ≤4 weeks after initiation of 
therapy and 5 enrolled by mistake. When including all 
histological tumor types, 189 patients were eligible for 
CA125 monitoring during therapy and 143 patients 
were eligible for CA125 monitoring during the subse­
quent follow­up period. During therapy, 1385 speci­
mens were collected with a median of seven samples 
per patient (range: 3–18 samples). The sampling inter­
val ranged from 3 to 84 days. The CA125 monitoring 
period was in median 125 days (range: 21–390 days). 
During follow­up, 2214 specimens were collected with 
a median of ten samples per patient (range: 3–56 sam­
ples). The sampling interval ranged from 4 to 180 days. 
The CA125 monitoring period was in median 330 days 
(range: 45–2160 days). Characteristics of the 189 eli­
gible patients at the start of the first­line chemotherapy 
appear in Table 1 and the treatments in Table 2. A total 
of 134 patients developed clinical progression cumu­
lated from therapy and follow­up. When consider­
ing serous tumors, only 112 patients were eligible for 
CA125 monitoring and 84 patients developed clinical 
progression cumulated from therapy and follow­up.
Figure 2. Distribution of CA125 lead times from individual patients cumulated from first-line chemotherapy 
and postchemotherapy follow-up. (A) CA125 lead time provided by criterion 1B among ten individual 
patients with clinical progression. (B) CA125 lead time provided by criterion 2A among 65 individual patients 
with clinical progression. (C) CA125 lead time provided by criterion 1B among eight individual patients with 
clinical progression. (D) CA125 lead time provided by criterion 2A among 43 individual patients with clinical 
progression.†Each dot represents the CA125 lead time obtained from a single patient. The dots below the solid 
line represent the individual positive lead time (>0 days) where CA125 progression preceded clinical progression. 
The dots on the solid line represent events where the individual lead time was zero (= 0 days) because the date 
of clinical progression coincided with the date of CA125 progression. The dots above the solid line represent the 
individual negative lead time (<0 days) where clinical progression preceded CA125 progression.
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Accuracy of the applied CA125 assessment 
criteria
Based on data cumulated from first­line chemotherapy, 
the subsequent follow­up and all histological tumor 
types, the accuracies of the criteria to detect CA125 incre­
ments starting from above and below the applied cut­off 
were similar with overlapping 95% CI (Table 3A). Crite­
ria 1A–1D did not provide FP increments but the num­
bers of FN events were high, 53–70%. Criteria 2A–2C 
provided 3–4 FP increments (same patients except one); 
all FP increments were registered during the post­therapy 
follow­up period at different time points depending on 
the individual criterion. The numbers of FN events were 
high (49–59%) (Table 3A). Inclusion of serous tumor 
types only, did not improve the accuracy (Table 3B). 
Thus, the number of FN events remained high both 
among patients with above and below cut­off concen­
trations (45–60 and 47–55%, respectively) (Table 3B). 
Overall, the positive predictive values of CA125 incre­
ments tended to be higher than the negative predictive 
values of stable concentrations.
CA125 lead times 
All histological tumor types
About 20% (38/189) of the eligible patients had 
CA125 baseline concentrations above cut­off and 
79% (30/38) of the patients developed clinical pro­
gression (Table 4A). Depending on the criterion, 
30–47% of the patients presented with lead times 
≥0 days (median: 27–87 days). The percentage of 
patients with lead times >0 days and ≤0 days ranged 
from 23–43 to 3–10%, respectively. About 80% 
(151/189) of the eligible patients had CA125 baseline 
concentrations below cut­off and 69% (104/151) of 
the patients developed clinical progression. Depend­
ing on the criterion, 41–51% of the patients presented 
with lead times ≥0 days (median: 41–46 days). The 
percentage of patients presenting with lead times 
>0 days and ≤0 days ranged from 34–49 to 14–29%, 
respectively.
Serous tumors
About 22% (25/112) of the eligible patients had 
CA125 baseline concentrations above cut­off and 80% 
(20/25) of the patients developed clinical progression 
(Table 4B). Depending on the criterion, 40–55% of the 
patients presented with lead times ≥0 days (median: 
26–85 days). The percentage of patients with CA125 
lead times >0 days and ≤0 days ranged from 30–50 
to 5–10%, respectively. About 78% (87/112) of 
the eligible patients had CA125 baseline concentra­
tions below cut­off and 74% (64/87) of the patients 
developed clinical progression. Depending on the 
criterion, 45–53% of the patients presented with lead 
times ≥0 days (median: 30–52 days). The percentage 
of patients presenting with lead times >0 days and 
≤0 days ranged from 39–52 and 11–28%, respectively. 
Overall, the lead times observed among all histological 
tumor types and serous tumors only appeared similar 
(Table 4A & B). Figure 2 illustrates a new format to pres­
ent detailed information of lead times in terms of pro­
gression among individual patients. Events with posi­
tive lead times (>0 days) are marked below the solid 
line; events with no lead time (=0 days) are marked 
on the solid line; and events with negative lead times 
(<0 days) are marked above the solid line.
Discussion
Tumor marker monitoring studies investigating the 
accuracy of criteria to detect increasing concentrations 
have frequently been based on heterogeneous designs 
making interpretation of results difficult [31]. The cur­
rent study followed the proposals of the EGTM and 
was designed as a prospective Phase II biomarker 
monitoring trial embedded into clinical drug trials 
where the tumor marker investigation was a secondary 
objective in relation to the clinical drug trial [26]. The 
current Phase II monitoring trial investigated the best 
performing criteria previously identified in a Phase I 
biomarker simulation study. The criteria were investi­
gated among a cohort of ovarian cancer patients with 
disease stages IC–IV receiving first­line chemotherapy 
and during the subsequent post­therapy follow­up 
period. A distinction was made when interpreting 
CA125 increments starting from baseline concentra­
tions above and below cut­off, respectively, because 
published criteria are focused on the nadir concentra­
tion of the increment in relation to the applied cut­off 
concentration.
It appears from Table 3A & B that approximately 
80% of the patients had baseline CA125 concentra­
tions below the applied cut­off. This was due to the 
inclusion procedure where 21% of the patients had 
early­stage disease (FIGO IA–IIC) with a low tumor 
burden (Table 1). For increments starting from concen­
trations above cut­off, neither of the criteria 1A–1D 
provided FP signals when all histological ovarian 
tumor types were considered (Table 3A). For baseline 
concentrations starting below cut­off, criteria 2A–2C 
each provided one temporary FP increment to above 
cut­off at different time points among the same three 
patients during post­therapy follow­up (Table 3A). Cri­
terion 2C provided an additional asynchronous FP 
increment. Three patients were under surveillance for 
additional 2–4 years without developing clinical pro­
gression, and one patient was followed for 6 months 
before the 5­year routine surveillance was completed 
and the patient was discharged from further follow­
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up without evidence of disease. This condition illus­
trates one of the most difficult situations in monitor­
ing where patients have a rising CA125, no evidence of 
progressive disease on imaging and no clinical symp­
toms of disease progression. It may be suggested that 
the patient should have been offered an additional year 
of surveillance. Bias may be less likely as the cause of 
the observed FP events because all measurements were 
performed at the same laboratory closely following the 
analytical quality. Additionally, the FP increments did 
not occur at the time point when the method to mea­
sure CA125 was changed. However, it may be specu­
lated that undetected temporary benign disease may 
have caused the FP increments [22,32].
Criteria 1A and 2A were developed to monitor 
patients during follow­up after primary therapy and 
have not been validated during first­line chemo­
therapy; consequently, it is difficult to compare the 
current data with former studies. As regards criteria 
1B–1D and 2B–2C, this is the first clinical study to 
report on their individual accuracy; their combined 
accuracy has been reported [7,20]. Overall, the accura­
cies of the criteria to interpret increments from above 
cut­off to higher levels among all histological tumor 
types were similar as were the accuracies of the crite­
ria interpreting increments from below to above cut­
off (Table 3A). However, a closer examination indi­
cates that the accuracies of the criteria in the current 
Phase II monitoring trial may support the accuracies 
reported in a previous Phase I simulation study [23]. 
Based on simulated data stratified for the lowest 
number of FP increments criterion 1B performed best 
among increments starting from above cut­off fol­
lowed by criteria 1A, 1D and 1C, respectively; and 
criterion 2A performed best among increments start­
ing from below cut­off followed by criteria 2B and 
2C. Owing to the nature of quantitative biochemi­
cal tests, there is an inverse relationship between the 
number of FP and FN events; consequently, the lower 
the number of FP events, the higher the number of 
FN events [33]. Accordingly, the criteria with the low­
est number of FP events in the Phase I simulation 
tests (criteria 1B and 2A) provided the highest num­
ber of FN events in the current Phase II monitoring 
trial (Table 3A).
It is often stated that CA125 is mainly expressed by 
ovarian tumors of the serous type. We therefore inves­
tigated the accuracy among patients whose tumors had 
this histological classification (Table 3B). However, 
the accuracy among serous tumors did not improve as 
compared with the accuracy when all histological types 
were included (Table 3B & A, respectively). In both situ­
ations, the observed numbers of FN events were rela­
tively high indicating that the validated CA125 criteria 
are unreliable to exclude clinical progression indepen­
dent of the baseline concentrations. Again, the criteria 
with the lowest number of FP events in the Phase I sim­
ulation tests (criteria 1B and 2A) provided the highest 
number of FN events in the current Phase II monitor­
ing trial (Table 3B). Other issues should also be consid­
ered in association with the reported FN events. Since 
the study period 1995–2001, the histological classifi­
cation system has been changed. Recent evidence has 
identified EOC as a heterogeneous disease with five 
distinct subtypes: high­grade serous, low­grade serous, 
clear cell, endometrioid and mucinous. Each subtype 
is associated with different biological characteristics, 
clinical behavior and prognosis [34,35]. There is now 
persuasive evidence to classify these five types of ovar­
ian carcinoma as different diseases [34,36,37]. Reclassifi­
cation of the patients according to current standards 
may provide an alternative distribution in the different 
subtypes. Situations with slow rate of CA125 increase 
due to low production in the tumor represent a chal­
lenge in terms of FN events. In an effort to elucidate 
whether the rate of FN events can be reduced with­
out numerous FP signals, it seems relevant to validate 
criteria specially designed to assess increments within 
the normal range and from below to slightly above the 
applied cut­off [38]. The reliability and the length of 
the positive lead time are important parameters for 
monitoring of cancer patients. A positive lead time 
enables early supplementary investigations, in other 
words, imaging and/or institution/change of therapy. 
The lead time provided by the criteria during clini­
cal monitoring was in accordance with the lead­time 
potential obtained in the simulation studies. The cri­
teria with the longest lead times in the current clinical 
Phase II monitoring trial provided the shortest time 
interval needed to detect 100% of TP CA125 incre­
ments in the simulation study [23]. A multicenter study 
by Rustin et al. reported on women with histologically 
confirmed epithelial ovarian, fallopian tube or serous 
primary peritoneal cancer in complete remission after 
first­line chemotherapy and baseline CA125 concen­
trations <35 U/ml [24]. When CA125 concentrations 
rose to ≥70 U/ml during the follow­up, the patients 
were randomized to early second­line chemotherapy or 
initiation of therapy at clinical or symptomatic relapse. 
They demonstrated a median lead time of 4.8 months; 
however, early treatment based on CA125 increments 
led to more chemotherapy, no difference in survival 
and worse quality of life. The median lead time in the 
current study among patients with CA125 increments 
starting from baseline CA125 concentrations <35 U/
ml cumulated from first­line chemotherapy and follow­
up was 1.0–1.7 months (Table 4A & B). It is difficult to 
argue that the short lead times observed in the cur­
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rent investigation would benefit the patients in terms 
of prolonged survival following early CA125­guided 
therapy.
One of the limitations of the current study is that 
the investigation was not blinded; the CA125 data 
were available throughout the study period together 
with the results of clinical examinations and imag­
ing [25]. This may have influenced the length of the 
positive lead time because the clinicians had the 
opportunity to request earlier imaging based on 
CA125 increments and thereby shorten the poten­
tial lead time. Another weakness is the changed 
histological classification of EOC which now con­
sidered a heterogeneous disease with five different 
subtypes [35]. Most likely, the new classification sys­
tem will provide a different distribution of patients 
among the two groups, all tumors and serous tumors 
only, respectively, inflicting the presented results 
with some uncertainty.
A further weakness adheres to the clinical response 
evaluation, which was based on criteria of the WHO 
in use at the time of the present study [27]. In 2000, 
the WHO standards were replaced by a set of new 
guidelines to evaluate the RECIST [39]. Re­evaluation 
of clinical response among the investigated patients 
according to the new standards may have some impact 
on the obtained results, but would hardly influence 
the overall impression of the validity of CA125 as a 
monitor of patients with EOC. Further limitations of 
the study could be due to the fact that first­line che­
motherapy and the subsequent follow­up period were 
not investigated individually because there were not 
enough patients entering the follow­up period allow­
ing a meaningful statistical analysis, and the perfor­
mance of each criterion was not investigated individ­
ually for each stage of disease due to a low number of 
patients within the individual subgroups.
Overall, the study supports a previous multicenter 
investigation suggesting that CA125 information can­
not stand alone but should be used in conjunction with 
other investigative procedures [24]. Performing sched­
uled CA125 testing to follow patients has a signifi­
cant cost. Therefore, it should be considered whether 
sustaining this cost is relevant without substantial 
benefit for the individual patient. In conclusion, the 
applied CA125 assessment criteria showed low sensi­
tivity (30–55%), low negative predictive value (28–
46%), high positive predictive value (90–100%) and 
short median lead time (26–87 days) among several 
patients.
Conclusion & future perspective
There is a need for supplementary markers and 
 alternative assessment criteria for patient surveillance.
The monitoring performance of the promising bio­
marker HE4 in combination with CA125 needs fur­
ther investigated among EOC patients undergoing 
first­line chemotherapy and during the subsequent 
follow­up period.
Evidently, identification of new biomarkers is impor­
tant, and the area is developing fast, in other words, 
circulating tumors cells, DNA and RNA fragments as 
well as epigenetic alterations [40,41].
Guidelines for conducting monitoring studies pro­
vided by the EGTM may be helpful when designing 
investigations of new serological markers for ovarian 
cancer [26,42].
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